Journal
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
Volume 23, Issue 3, Pages 131-134Publisher
PROUS SCIENCE, SA
DOI: 10.1358/mf.2001.23.3.627945
Keywords
diabetic neuropathy; lisinopril; streptozotocin
Categories
Ask authors/readers for more resources
Streptozotocin (STZ)-induced diabetic neuropathy in rats was monitored by measuring the motor nerve conduction velocity (MNCV) and histopathology of the tibial nerve. Pretreatment with lisinopril (2 mg/kg p.o., 5 days prior to STZ and continued for 10 weeks) significantly (p < 0.01) prevented deterioration of MNCV ms compared to STZ-diabetic animals. Nerve sections from the lisinopril pretreated group revealed less structural damage as compared to STZ-diabetic rats. However lisinopril haul no effect on blood sugar i.e., it did not alter the diabetic state. It is concluded that lisinopril prevents the development of experimental diabetic neuropathy in STZ-induced diabetic rats. (C) 2001 Prous Science. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available